Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,664

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,664 results for “plaque”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov36/100

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

ClinicalTrials.gov study NCT03818035. IPD Sharing: YES. Countries: 2. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

ClinicalTrials.gov study NCT01163253. IPD Sharing: YES. Countries: 36. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis

ClinicalTrials.gov study NCT00988637. IPD Sharing: Not stated. Countries: 2. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

ClinicalTrials.gov study NCT03536884. IPD Sharing: YES. Countries: 11. Publications: 11.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

ClinicalTrials.gov study NCT01241591. IPD Sharing: Not stated. Countries: 26. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

ClinicalTrials.gov study NCT04102007. IPD Sharing: YES. Countries: 8. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

ClinicalTrials.gov study NCT00773734. IPD Sharing: Not stated. Countries: 2. Publications: 8.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

ClinicalTrials.gov study NCT01186744. IPD Sharing: Not stated. Countries: 12. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

ClinicalTrials.gov study NCT01988103. IPD Sharing: YES. Countries: 1. Publications: 3.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

ClinicalTrials.gov study NCT04655313. IPD Sharing: Not stated. Countries: 3. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-ob

ClinicalTrials.gov study NCT05360446. IPD Sharing: YES. Countries: 18. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

ClinicalTrials.gov study NCT03090100. IPD Sharing: Not stated. Countries: 9. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

ClinicalTrials.gov study NCT02576678. IPD Sharing: YES. Countries: 4. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

ClinicalTrials.gov study NCT01000727. IPD Sharing: YES. Countries: 36. Publications: 5.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

ClinicalTrials.gov study NCT02070965. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

ClinicalTrials.gov study NCT03478787. IPD Sharing: YES. Countries: 9. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis

ClinicalTrials.gov study NCT02107482. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

ClinicalTrials.gov study NCT00521339. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

ClinicalTrials.gov study NCT03956355. IPD Sharing: NO. Countries: 2. Publications: 4.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

ClinicalTrials.gov study NCT05600036. IPD Sharing: NO. Countries: 3. Publications: 0.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record